The phase I trial CBYL719X2101 (NCT01219699) included 134 heavily pre-treated patients with PIK3CA alterations across advanced cancer types and demonstrated sensitivity to the single agent alpelisib. The gene discussed is PIK3CA; the disease is cancer.